Organization · Venture Capital
Kineticos Life Sciences
Kineticos Life Sciences is a Raleigh, NC-based growth equity and venture capital firm focused on investing in life sciences companies that aim to improve patient outcomes. They target specialized pharmaceutical services, therapeutic technologies, and enabling tools across various stages of development.
Overview
What Kineticos Life Sciences does
What Kineticos Life Sciences is
Kineticos Life Sciences is a Raleigh, NC-based growth equity and venture capital firm focused on investing in life sciences companies that aim to improve patient outcomes. They target specialized pharmaceutical services, therapeutic technologies, and enabling tools across various stages of development.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Structured capabilities
- Funder
- Last reviewed
- April 9, 2026
Official channels
Find Kineticos Life Sciences elsewhere
Open the official website or a supported primary organization account.
Capability profile
Kineticos Life Sciences as a funder
Investment thesis
Kineticos Life Sciences aims to support transformative technologies that address significant health challenges and improve patient care.
Focus narrative
Kineticos invests in high-growth opportunities across the life sciences ecosystem, targeting specialized pharmaceutical services, oncology, neurodegenerative diseases, rare diseases, and antimicrobial resistance (AMR). The firm operates primarily in the United States and aims to bridge the gap between venture and growth equity investing.
Value beyond capital
Kineticos provides value to its portfolio companies through operator-led investing, leveraging deep scientific expertise across multiple therapeutic areas and molecule types. The firm supports organic growth, strategic acquisitions, and international expansion, enhancing the capabilities and market reach of its investments.
Focus and fit
- Stages
- Pre-seed · Seed · Seed+ · Series A · Series B · Growth Equity
- Sectors
- Biotech · Healthcare · Fintech · Health Data · Medical Devices · Pharma Tech · Diagnostics
- Regions
- United States
Availability
- Currently deploying
- Yes
Portfolio and track record
Portfolio context
Kineticos has a diverse portfolio that includes notable companies such as: Amylyx: Developing therapeutics for neurodegenerative disorders. Arranta Bio: A CDMO specializing in microbiome and mRNA therapies, acquired by Recipharm. Clarametyx: A clinical-stage biotech focused on anti-biofilm antibodies for cystic fibrosis. DIANT Pharma: Innovating continuous processing technology for nanoparticles. Endolytix: Treating non-tuberculous mycobacterial pulmonary disease using bacteriophage enzymes. EnteroBiotix: Developing microbiome therapeutics for hepatic encephalopathy and graft versus host disease.
Common questions
What to know about Kineticos Life Sciences
Upseed classifies Kineticos Life Sciences under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
April 9, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.